Cubicin generic
Cubicin is an antibiotic drug owned by Cubist Pharmaceuticals LLC. The active ingredient in Cubicin is daptomycin. This medicine was first authorized for market use on September 12, 2003, and is available in powder form for intravenous use.
When will Cubicin generic be available?
The generic version of Cubicin might be available after November 23, 2030. This generic release date is based on the expiry date of the last standing patent, which is US9138456 titled 'Lipopeptide compositions and related methods', scheduled to expire on this date.
Cubicin uses
Cubicin is primarily used for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections including those with right-sided infective endocarditis. The effectiveness of Cubicin in eliminating these infections is attributed to its active ingredient, daptomycin.
Cubicin patent expiration
Cubicin has a total of 2 active patents. The last patent, US9138456 titled 'Lipopeptide compositions and related methods', is slated to expire on November 23, 2030. This patent expiry will provide an opportunity for the release of Cubicin generic. Below are the details of the patent: